Skyhawk Therapeutics Announces Agreement with Takeda for Neurodegenerative Diseases

May 6, 2019

WALTHAM, Mass., May 6, 2019 /PRNewswire/ — Skyhawk Therapeutics, Inc. (Skyhawk) today announced a strategic collaboration with Takeda Pharmaceutical Company Limited (Takeda) in which Skyhawk will use its SkySTAR™technology platform to discover and pre-clinically develop innovative small molecule treatments directed to certain neurological disease targets. The agreement grants Takeda an exclusive worldwide license to develop and commercialize compounds and products directed to multiple targets while Skyhawk receives an upfront payment and is eligible to receive future milestone payments and royalties. As part of the agreement, Takeda will be responsible for clinical development and potential commercialization.

Skyhawk will use its SkySTAR™ platform to develop drug candidates directed to multiple targets for neurodegenerative diseases.  In exchange Takeda will pay Skyhawk an upfront payment, future milestone payments and royalties.

Fullress release here.